Saxenda Shortage; New ADA Guidance; Cheap Test for Osteoporosis Risk?
(MedPage Today) -- The shortage of weight-loss drugs now extends to liraglutide (Saxenda). (Fierce Pharma)
Compared with DPP-4 inhibitors, SGLT2 inhibitors helped reduce recurrent gout flare-ups and hospitalizations in people with type 2 diabetes...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Gout | Orthopaedics | Osteoporosis | Pharmaceuticals | SGLT2 Inhibitors | Victoza | Weight Loss